Protalix BioTherapeutics (PLX) Issues Positive Update on Low-Dose PRX-102 in Fabry Disease
Tweet Send to a Friend
Protalix BioTherapeutics (NYSE: PLX) announced positive long term data from the 0.2mg, or lowest dose, of the Company's phase I/II ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
